Trastuzumab is a monoclonal antibody that targets the HER2 receptor and has been administered in the context of HER2-positive breast cancer patients for over 20 years, where it has been shown to improve progression-free survival (PFS) and OS [32,33]. This evidence concerns the gene ERBB2 and breast cancer.